A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 22 Jul 2024 According to a Johnson & Johnson media release, the company announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).
- 17 Jul 2024 According to a Johnson & Johnson media release, additional data from this study presented at the s American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which is being held from May 28-31 in Miami, Florida.
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.